

# Optimal control using pontryagin's maximum principle: Tuberculosis spread case

Muhammad Iqbal Widiaputra\*, Ahmad Hanif Asyhar, Wika Dianita Utami, Putroue Keumala Intan, Dian Yuliati, Muhammad Fahrur Rozi

**Abstract**—Tuberculosis is one of the deadliest infectious diseases in the world. In 2020, 9.9 million people were infected and 1.5 million died. East Java province ranks third with 43,268 tuberculosis cases. This research aims to determine the results of the tuberculosis disease model and simulation without and with the use of optimal control. The mathematical model SEIR is a model that can analyze the spread of the disease tuberculosis. In this research, a variable treatment compartment to the SEIR model. It used 4 antibiotics in the intensive phase and added Isoniazid and Rifampicin in the advanced phase as the optimal control parameters. Optimal control uses Pontryagin's maximum principle as the derivative to modify the SEIR model and is described by a Runge-Kutta order 4 scheme. It shows both the useful parameters in the optimal control with a maximum value of 1 and plots where the effect of optimal control exists further constrained the people infected with Tuberculosis.

**Index Terms**—Optimal Control, Tuberculosis, Mathematical Modeling.

## I. INTRODUCTION

**T**UBERCULOSIS, caused by *Mycobacterium tuberculosis*, remains the leading cause of death worldwide. Especially in 2020, 9.9 million people were infected and 1.5 million died [1]. Indonesia is one of the developing countries with the highest number of tuberculosis cases in the world, with a total of 824,000 tuberculosis infections and 93,000 deaths per day [2]. East Java was chosen as this study because nonadherence to recommended medications in the community remained high, with patient abandonment and inconsistency, and the number of cases in 2021 was 43,268 live [3] [4] [5]. It is necessary to divide the disease into two stages, an intensive stage, and an advanced stage, and to administer drugs regularly [6]. Also in terms of carrying out multi-sectoral campaigns for various interest groups, for example: Advocacy, standby work, association with stakeholders [7].

The prevalence of tuberculosis disease has been discussed in several previous studies. In the first research, SEIR (Susceptible, Exposed, Infection, Recovery) models were used to generate independent effects from each compartment, analyzing tuberculosis transmission at the disease-free stable point and reproductive numbers for system performance equations within compartments [8]. Subsequent studies discussed deterministic and probabilistic differences demonstrating successful modeling of tuberculosis infection using the transmission dynamics of the stochastic SEIR (Susceptible, Exposed, Infection, Recovery) model over time [9].

The difference for this research is adding 4 antibiotics in the form of Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide were administered for the first 2 months, followed by the addition of a compartment variable to the regimen containing optimal control parameters for the intensive phase every 2 weeks continuously. Followed by the addition of a compartmental variable to the regimen containing optimal control parameters for the intensive phase to maximize the process of treatment. The next step is adding the drugs Isoniazid and Rifampicin to kills persistent bacteria and prevent them from reappearing for a longer time [10][11].

This research uses the dynamic system as the control input and uses the Pontryagin Maximum Principle. It is an optimal control technique to determine the maximum value for a particular system [12][13]. It can include studies that help analyze optimal control models in the SIRC (Susceptibility, Infection, Recovery, Cross-Immunity) model of influenza [14]. Various studies are available to support the Pontryagin Maximum Principle. For example, this research can analyze and formulate an age-classified structured tuberculosis transmission model and apply optimal control strategies by adding variables of prevention, latent chemoprophylaxis, and active treatment efforts also useful [15].

From the above explanation, this research aims to determine the result of the tuberculosis disease model and simulation without and with the use of optimal control.

## II. FORMULATION MODEL

### A. Assumption Modification

In this study, we modify the TB SEIR model using the following assumptions: It is contracted only through close contact with people who are not immune to tuberculosis. The combination of age, sex, social class, human race, and climatic conditions does not affect the likelihood of human exposed. Mortality rates were assumed to be stable and similar in all individuals, and mortality rates were continuously adjusted as data were completed. In this case, the population is fixed. Where  $\mu$  is the proportion of non-immune humans born into the vulnerable class, and  $\mu S$  is the natural death of the vulnerable subpopulation. infections in confined spaces. No emigration, immigration, or both, or death within the population. Each plot has the same natural mortality rate for the population [8].

The assumptions, compartment diagram model, and parameters used for the development of the above research are as follows: The population rate ( $\alpha$ ) is different from the natural mortality rate ( $\mu$ ), and Mortality from tuberculosis infection

M. I. Widiaputra\*, A. H. Asyhar, W. D. Utami, P. K. Intan, D. Yuliati, M. F. Rozi are with the Universitas Islam Negeri Sunan Ampel Surabaya, Indonesia e-mail:iqbalwidiaputra257@gmail.com

Manuscript received July 18, 2023; accepted September 14, 2023.

( $\phi$ ) is different from natural mortality ( $\mu$ ). This is because the probability of dying from tuberculosis is 50% compared to natural death [16].

### B. TB Model & Parameters

Below are the modified tuberculosis models from the [8] study and the parameters used:




Fig. 1: Susceptible, Exposed, Infected, Recovery (SEIR) TB Model

Based on the compartment diagram in (Fig. 1), we can write the following equation:

$$\begin{aligned} S^\bullet(t) &:= \frac{dS(t)}{dt} = \alpha N + \kappa R(t) - S(t) \left( \frac{\beta I(t)}{N} + \mu \right) \\ E^\bullet(t) &:= \frac{dE(t)}{dt} = \frac{\beta S(t) I(t)}{N} - E(t) (\epsilon + \mu) \\ I^\bullet(t) &:= \frac{dI(t)}{dt} = \epsilon E(t) - I(t) (\gamma + \phi) \\ R^\bullet(t) &:= \frac{dR(t)}{dt} = \gamma I(t) - R(t) (\mu + \kappa) \end{aligned} \quad (1)$$

where :  $N = S(t) + E(t) + I(t) + R(t)$   
:  $S(0) = S_0 \geq 0; E(0) = E_0 \geq 0; I(0) = I_0 \geq 0; R(0) = R_0 \geq 0$

TABLE I: Research Parameters

Parameter	Description
$\alpha$	Rate of the population
$\mu$	Rate of natural deaths
$\beta$	Comparison of TB-infected population and susceptible TB rate
$\epsilon$	Rate of the exposed population who have been infected with TB
$\phi$	Mortality from TB infection
$\gamma$	The rate at which the infected population can recover
$\kappa$	The proportion of recovered patients who are susceptible to getting TB

## III. FORMULATION OF OPTIMAL CONTROL

### A. Optimal Control Models

This section presents the problem of optimal control of the population dynamic of the prevalence of tuberculosis disease using optimal control parameters for the intensive care stage ( $u_1$ ) in the compartment between the TB-infected population and the treatment population. increase. Moreover, the optimal control parameters for advanced stage ( $u_2$ ) lie in the range between the subpopulations receiving treatment and those

recovering from TB. All these optimal controls can be modeled as follows:

$$\begin{aligned} S^\bullet(t) &:= \frac{dS(t)}{dt} = \alpha N + \kappa R(t) - S(t) \left( \frac{\beta I(t)}{N} + \mu \right) \\ E^\bullet(t) &:= \frac{dE(t)}{dt} = \frac{\beta S(t) I(t)}{N} - E(t) (\epsilon + \mu) \\ I^\bullet(t) &:= \frac{dI(t)}{dt} = \epsilon E(t) - I(t) (u_1(t) + \phi) \\ T^\bullet(t) &:= \frac{dT(t)}{dt} = u_1(t) I(t) - T(t) (u_2(t) + \phi) \\ R^\bullet(t) &:= \frac{dR(t)}{dt} = u_2(t) T(t) - R(t) (\mu + \kappa) \end{aligned} \quad (2)$$

where :  $N = S(t) + E(t) + I(t) + T(t) + R(t)$   
:  $S(0) = S_0 \geq 0; E(0) = E_0 \geq 0; I(0) = I_0 \geq 0; T(0) = T_0 \geq 0; R(0) = R_0 \geq 0$

### B. Hamiltonian Function

From the above (Eq. 2), we can implement the optimal control strategy by minimizing the value weighting function as:

$$J[u_1(t), u_2(t)] = \int_{t_0}^{t_f} (A_1 I(t) + A_2 T(t) + C_1 u_1^2(t) + C_2 u_2^2(t)) dt \quad (3)$$

where :

- 1)  $t_0$  = initial condition in first year, and
- 2)  $t_f$  = final condition in seventh year

Where  $C_1$  and  $C_2$  are cost weights for reducing the number of tuberculosis infections and treatment failure deaths. The next step is to find the optimal control values such that:

$$\begin{aligned} J(u_1^*, u_2^*) &= \min \{ J(u_1, u_2) : u \in U \} \\ U &= \{ u(t) : 0 \leq u_i(t) \leq 1, \forall t \in [t_0, t_f]; i = 1, 2 \} \end{aligned} \quad (4)$$

If the optimal control value is 0 within this interval, this has no effect on the control performed. Also, when the value is 1, the optimal control cost is maximized.

### C. Pontryagin Maximum Principle

Optimal control  $u_1^*$  and  $u_2^*$  are model constraints (Eq. 2) using *Pontryagin maximum principle* [17][18][15]. This principle combines the equations (3) and (4) to solve the problem of minimizing the Hamiltonian  $\mathcal{H}$  with respect to  $u_1$  and  $u_2$  such as:

$$\begin{aligned} \mathcal{H}(S(t), E(t), I(t), T(t), R(t), u_1(t), u_2(t), \lambda_i(t), t) \\ = \left( A_1 I(t) + A_2 T(t) + C_1 u_1^2(t) + C_2 u_2^2(t) \right) + \sum_{i=1}^5 \lambda_i f_i \end{aligned} \quad (5)$$

If  $f_i$  is specified on the right side of the model (Eq.2), the variable *adjoint* satisfies the *co-state* system of equations as:

$$\begin{aligned}
\lambda_1^{**}(t) &:= -\left(\frac{\partial \mathcal{H}^*(t)}{\partial S^{**}(t)}\right) \\
&= -\left(\lambda_1^*(t)\left[-\frac{\beta I^*(t)}{N} - \mu\right] + \lambda_2^*(t)\frac{\beta I^*(t)}{N}\right) \\
\lambda_2^{**}(t) &:= -\left(\frac{\partial \mathcal{H}^*(t)}{\partial E^{**}(t)}\right) \\
&= -\left(\lambda_2^*(t)\left[-\varepsilon - \mu\right] + \lambda_3^*(t)\varepsilon\right) \\
\lambda_3^{**}(t) &:= -\left(\frac{\partial \mathcal{H}^*(t)}{\partial I^{**}(t)}\right) \\
&= -\left(A_1 + \left[\frac{\beta S^*(t)}{N}\right]\right)\left(\lambda_1^*(t) - \lambda_2^*(t)\right) + \\
&\quad \lambda_3^*(t)\left[-u_1^*(t) - \phi\right] + \lambda_4^*u_1^*(t) \\
\lambda_4^{**}(t) &:= -\left(\frac{\partial \mathcal{H}^*(t)}{\partial T^{**}(t)}\right) \\
&= -\left(A_2 + \lambda_4^*(t)\left[-u_2^*(t) - \phi\right] + \lambda_5^*(t)u_2^*(t)\right) \\
\lambda_5^{**}(t) &:= -\left(\frac{\partial \mathcal{H}^*(t)}{\partial R^{**}(t)}\right) \\
&= -\left(\lambda_1^*(t)\kappa + [\mu - \kappa]\lambda_5^*(t)\right)
\end{aligned} \tag{6}$$

with transverse initial condition:  $\lambda_i(t_f) = 0; i = 1, 2, 3, 4, 5$

The next step needed to satisfy the optimal control  $u = (u_1^*, u_2^*)$  by minimizing the Hamiltonian with respect to  $U$  as:

$$u_1^*(t) = \begin{cases} 0, & u_1(t) \leq 0 \\ \frac{(\lambda_3(t) - \lambda_4(t))I(t)}{2C_1}, & 0 < u_1(t) < 1 \\ 1, & u_1(t) \geq 1 \end{cases} \tag{7}$$

$$u_2^*(t) = \begin{cases} 0, & u_2(t) \leq 0 \\ \frac{(\lambda_3(t) - \lambda_4(t))I(t)}{2C_1}, & 0 < u_2(t) < 1 \\ 1, & u_2(t) \geq 1 \end{cases} \tag{8}$$

Next, solve the system *state*  $x^*(t) = \frac{\partial \mathcal{H}}{\partial \lambda}$  . where  $x = (S, E, I, T, R), \lambda = (\lambda_1, \lambda_2, \lambda_3, \lambda_4, \lambda_5)$  (using initial condition  $x_0$ ). Finally, the system of equations *co-state*  $\lambda^*(t) = -\frac{\partial \mathcal{H}}{\partial x}$  using the transverse condition  $\lambda_i(t_f) = 0, i = 1, 2, 3, 4, 5$ .

Based on all the above steps, the optimal control  $(u_1^*, u_2^*)$  obtains the following theorem.

**Theorem 1.** optimal control  $(u_1^*, u_2^*)$  minimizing value weightness for  $J(u_1^*, u_2^*)$  to  $U$  is

$$u_1^*(t) = \max\left\{0, \min\left\{1, \frac{(\lambda_3(t) - \lambda_4(t))I(t)}{2C_1}\right\}\right\}$$

$$u_2^*(t) = \max\left\{0, \min\left\{1, \frac{(\lambda_4(t) - \lambda_5(t))T(t)}{2C_2}\right\}\right\}$$

## IV. RESULT AND DISCUSSION

### A. Parameter Value

The parameters used in this study are:  $\alpha = 0.70$  [19];  $\mu = 0.0047$  [20];  $\beta = 0.5853$  [21];  $\varepsilon = 0.2007$  [22];  $\phi = 0.09$  [23];  $\gamma = 0.75$  [15]; and  $\kappa = 0.02$  [21], with initial condition  $S(0) = 38,606,470$ ;  $E(0) = 199,574$ ;  $I(0) = 48,739$ ;  $T(0) = 2,458$ ; and  $R(0) = 17,320$ . To complete this simulation, first, use Runge-Kutta Order 4 *Forward* in the *state* equations. A second eventuality used *Backward* of RKO4 in the *co-state* equations.

The assumption used in this research that if the value of  $C_1$  based on the intensive care stage is greater than  $C_2$ , 4 antibiotics are required to prevent the emergence of drug immunity. Then, in advanced stages, it only needs two antibiotics. Of course, it helps prevent relapses and reduce the number of tuberculosis infections [10]. Therefore, the weights used in the objective function of the (Eq. 3) are  $C_1 = 90$  and  $C_2 = 70$  [15]. In addition, the values of  $A_1$  and  $A_2$ , which describe the coefficients of the population infected with tuberculosis and undergoing treatment, are 150 and 120, respectively [24].

### B. Numerical Simulation

Below are the simulation results for the TB model without and with optimal control, consisting of: optimal control simulation diagram; simulation chart of subpopulations susceptible to TB; subpopulations exposed to TB; TB-infected subpopulation; and subpopulation recovery of TB; except in the treatment subpopulation it is not shown because there are not different charts without and with optimal control.

From the above calculations by selecting the values of  $A_1, A_2, C_1,$  and  $C_2$ . Each  $u_1^*$  and  $u_2^*$  is 1, which means that the two optimal control parameters in the treatment stage compartment are useful for reducing the number of tuberculosis patients.

As well as, with details on previously treated patients at risk of resistance. The re-treatment mix consists of 5 drugs for the intensive phase and 3 drugs for the continuation phase. During the intensive phase at least 2 of the drugs administered must still be effective [25].




Fig. 2: Susceptible of Subpopulation




Fig. 4: Subpopulation of Infected

Based on the figure above (2) for the optimal uncontrolled graph with a large increase from year 1 to year 7, with additional subpopulations added each year there after. Unlike optimal control charts, there is a sharp decline, resulting in a decreasing number of subpopulations each year. This is due to the optimal control action to control the number of people moving to the next step.

There is a big difference in the figure (4). We observe that the uncontrolled graph increases. Optimal control occurs in this compartment in the form of four powerful antibiotics. At this stage, infected patients are given drugs such as: Isoniazid, Rifampicin, Ethambutol, and Pyrazanamide and will be directly monitored daily to prevent the emergence of drug resistance. The presence of optimal controls reduces the peak number of highly influential individuals before moving on to the next compartment.




Fig. 3: Subpopulation of Exposed

From the figure (3), we can see that the plots without and with optimal control converge at year 1 and start to spread out from year 2 to year 7. This suggests that TB-exposed subpopulations exist only in enclosed areas and are best controlled in other compartments, thus affecting population numbers and preventing them from entering the next compartment. It can be concluded that the population will decrease significantly in.




Fig. 5: Subpopulation of Recovery

The figure (5) shows that there is a large difference between the figures without and with optimal control. Without optimal control, the curve decreased dramatically from his 1st year to his 7th year, and not a single person recovered from TB. This differs from the best control, where the patient continues to follow existing treatment protocols to declare cure, Isoniazid and Rifampin for 4 months. The difference between the two plots is that the change in infection rate in individuals does not decrease significantly compared to no controls before individuals who recover from TB and become susceptible to TB again become ill. There is an optimal contrast such as.

### V. CONCLUSION

The usage of optimal control parameters in the tuberculosis model shows a very significant effect on changes in the

population of sufferers and TB cure. The need for intensive and advanced treatment can be carried out if TB patients are consistent in taking TB antibiotics so that resistance does not occur.

## REFERENCES

- [1] K. Floyd, "Global Tuberculosis Report 2021," <https://news.ge/anakliisporti-aris-qveynis-momava>, World Health Organization, Geneva, Tech. Rep., 2021.
- [2] Rokom, "Tahun ini, Kemenkes Rencanakan Skrining TBC Besar-besaran," <https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20220322/4239560/tahun-ini-kemenkes-rencanakan-skrining-tbc-besar-besaran/>, 2021. [Online]. Available: <https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20220322/4239560/tahun-ini-kemenkes-rencanakan-skrining-tbc-besar-besaran/>
- [3] Dinkes Jatim, "Profil Kesehatan 2021," Surabaya, Tech. Rep., 2021.
- [4] S. Sofiana, "Kasus Tuberkulosis Meningkat di Jawa Timur, Diklaim Penyebabnya Adalah," <https://surabaya.tribunnews.com/2019/04/06/kasus-tuberculosis-di-jatim-meningkat-diklaim-penyebabnya-adalah>, 2019.
- [5] R. N. Rizqiya, "Hubungan Stigma Masyarakat Dengan Kepatuhan Minum Obat Pasien Tb Paru Di Puskesmas Puhjark Kecamatan Pleman Kabupaten Kediri," *Jurnal Ilmiah Kesehatan Keperawatan*, vol. 17, no. 1, p. 66, 2021.
- [6] N. Rafiqua, "Berbagai Jenis Obat Antituberkulosis (OAT) yang Umum Dipakai dalam Pengobatan," <https://www.sehatq.com/artikel/jangan-asal-pengobatan-tbc-mesti-disesuaikan-dengan-jenisnya>, 2022. [Online]. Available: <https://www.sehatq.com/artikel/jangan-asal-pengobatan-tbc-mesti-disesuaikan-dengan-jenisnya>
- [7] World Health Organization, "The End Strategy TB," *The End TB Strategy*, vol. 53, no. 9, pp. 1689–1699, 2015.
- [8] K. Das, B. S. Murthy, S. A. Samad, and M. H. A. Biswas, "Mathematical transmission analysis of SEIR tuberculosis disease model," *Sensors International*, vol. 2, no. April, p. 100120, 2021. [Online]. Available: <https://doi.org/10.1016/j.sintl.2021.100120>
- [9] F. O. Mettle, P. Osei Affi, and C. Twumasi, "Modelling the Transmission Dynamics of Tuberculosis in the Ashanti Region of Ghana," *Interdisciplinary Perspectives on Infectious Diseases*, vol. 2020, p. 16, 2020.
- [10] Departemen Kesehatan RI, "Pharmaceutical care untuk penyakit tuberkulosis," Departemen Kesehatan RI, Jakarta, Tech. Rep. 6, 2005. [Online]. Available: [http://binfar.depkes.go.id/dat/lama/1309242859\\_YANFAR.PC\\_TB\\_1.pdf](http://binfar.depkes.go.id/dat/lama/1309242859_YANFAR.PC_TB_1.pdf)
- [11] H. Wouk, *Health alert-Tuberculosis*, J. Bean, Ed. Tarrytown: Michelle Bisson, 2010.
- [12] J. Harmand, C. Lobry, A. Rapaport, and T. Sari, *Optimal Control in Bioprocesses (Pontryagin's Maximum Principle in Practice)*, B. L. C.-i.-P. Data, Ed. London: ISTE, 2019, vol. 3.
- [13] N. Ilmayasinta, L. Hanafi, and S. & Sanjaya, "Optimal Control of Lipid Extraction Model on Microalgae Using Linear Quadratic Regulator (LQR) and Pontryagin Maximum Principle (PMP) Methods," *MATEMATIKA*, no. Special, pp. 129–141, 2018.
- [14] Z. Zhang, W. Zhang, K. Sooppy, N. Gul, A. Zeb, and V. Vijayakumar, "Dynamical aspects of a tuberculosis transmission model incorporating vaccination and time delay," *Alexandria Engineering Journal*, 2022. [Online]. Available: <https://doi.org/10.1016/j.aej.2022.11.010>
- [15] U. Dyah, F. Riyudha, and H. Tasman, "Optimal control of a discrete age-structured model for tuberculosis transmission," *Heliyon*, vol. 6, no. July 2019, p. 03030, 2020. [Online]. Available: <https://doi.org/10.1016/j.heliyon.2019.e03030>
- [16] D. A. Rohilla, *Handbook of Bacteriology*, 2010th ed., Shivangi Computers, Ed. New Delhi: Oxford Book Company, 2010.
- [17] D.-p. Gao and N.-j. Huang, "Optimal Control Analysis of a Tuberculosis Model," *Applied Mathematical Modelling*, vol. 58, no. January, pp. 47–64, 2020.
- [18] S. Lenhart and J. T. Workman, *Optimal Control Applied to Biological Models*, 1st ed., E. O. Etheridge, Alison M., Gross, Louis J., Lenhart, Suzanne., Maini, Philip K., Ranganathan, Shoba., Safer, Hershel M., Voit, Ed. Florida: Taylor and Francis, 2007.
- [19] BPS Jawa Timur, "Provinsi Jawa Timur Dalam Angka 2022," Badan Pusat Statistik Provinsi Jawa Timur, Surabaya, Tech. Rep., 2022.
- [20] S. Kasereka Kabunga, E. F. Doungmo Goufo, and V. Ho Tuong, "Analysis and simulation of a mathematical model of tuberculosis transmission in Democratic Republic of the Congo," *Advances in Difference Equations*, vol. 2020, no. 1, 2020. [Online]. Available: <http://dx.doi.org/10.1186/s13662-020-03091-0>
- [21] K. G. Mekonen and L. L. Obsu, "Mathematical modeling and analysis for the co-infection of COVID-19 and tuberculosis," *Heliyon*, vol. 8, no. 10, p. e11195, 2022. [Online]. Available: <https://doi.org/10.1016/j.heliyon.2022.e11195>
- [22] T. Akman Yildiz and E. Karaoglu, "Optimal control strategies for tuberculosis dynamics with exogenous reinfections in case of treatment at home and treatment in hospital," *Nonlinear Dynamics*, vol. 97, no. 4, pp. 2643–2659, 2019.
- [23] B. Fatima and G. Zaman, "Co-infection of Middle Eastern respiratory syndrome coronavirus and pulmonary tuberculosis," *Chaos, Solitons and Fractals*, vol. 140, p. 110205, 2020. [Online]. Available: <https://doi.org/10.1016/j.chaos.2020.110205>
- [24] I. Abouelkheir, M. Alkama, F. Elkhal, and M. Rachik, "Optimal Control Strategy of a Tuberculosis Epidemic Model with Drug Resistant TB," *International Journal of Science and Research*, vol. 4, no. 3, pp. 2013–2016, 2015.
- [25] B. POM RI, "Antituberkulosis," <https://pionas.pom.go.id/ioni/bab-5-infeksi/52-tuberkulosis-dan-leprosi/521-antituberkulosis>, Jakarta, 2015.